Loading quotes...

Forecast

The analysts' average price target is €362.47 (-9.79%). The median is €368.04 (-8.40%).

Buy	22
Hold	16
Sell	3

News Go to news feed

Amgen achieves phase 3 success with Tezspire in eosinophilic esophagitis

In the phase 3 trial CROSSING, Tezspire from Amgen (in collaboration with AstraZeneca) met both primary and key secondary endpoints in patients with eosinophilic esophagitis. After 24 weeks, histological remission rates were 64.8% (210 mg) and 68.9% (420 mg) versus 3.5% for placebo; the effect persisted at 52 weeks. Adverse events were mainly respiratory infections, headache and diarrhea; Amgen and AstraZeneca now plan to discuss the data with regulators to make the drug available quickly. » More on deraktionaer.de
Amgen outpaces Merck on dividend growth and durability

Amgen yields about 2.6% versus Merck's 2.29% and has delivered consistent ~6% annual dividend increases compared with Merck's smaller mid-single-digit hikes. Amgen reports broader revenue diversification with 17 products at >$1bn, $3.5bn quarterly free cash flow and raised 2026 EPS guidance, supporting dividend coverage despite higher leverage. Merck relies heavily on Keytruda, faces peak-penetration risks and absorbed a $5.7bn acquisition charge that pushed Q2 GAAP results to a loss, leaving its dividend growth profile less certain. » More on finance.yahoo.com
Amgen shares drop after Novartis Lp(a) failure raises doubts about olpasiran

Amgen fell about 5% after Novartis reported that pelacarsen substantially lowered Lp(a) but failed to reduce major cardiovascular events, challenging the hypothesis that Lp(a) lowering cuts clinical outcomes. Olpasiran, Amgen’s siRNA, achieves deeper Lp(a) reductions in earlier trials (>95% vs ~80%) but the Novartis miss lowers its probability of success rather than disproving it. Amgen’s diversified portfolio and other late‑stage assets cushion the impact, while olpasiran’s own outcomes will determine its ultimate valuation effect. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Amgen has already paid €6.53 in dividends. The last payout was in September.

Financials

In the last quarter, Amgen had revenue of €8.81B and net profit of €2.08B

(EUR)	June 2026	YoY
Revenue	8.81B	13.27%
Gross profit	6.35B	21.51%
Net profit	2.08B	71.28%
EBITDA	3.99B	30.00%

Fundamentals

Metric	Value
Market capitalization	€213.18B
Number of shares	540.63M
52-week high/low	€404.83 - €258.53
Dividend yield	2.16%
Dividends TTM	€8.55
Beta	0.41
P/E ratio	27.08
PEG ratio	0.86
P/B ratio	20.29
P/S ratio	6.23

Company profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Name	Amgen
CEO	Robert A. Bradway
Headquarters	Thousand Oaks, ca USA
Website	investors.amgen.com
Sector	Health Care
Industry	Biotechnology
IPO	06/17/1983
Employees	31,500